Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy.

Journal: Neurological Sciences : Official Journal Of The Italian Neurological Society And Of The Italian Society Of Clinical Neurophysiology
Treatment Used: Amino Acid Supplementation
Number of Patients: 2
MediFind Summary

Summary: This study reported on patients with autosomal dominant (AD) spastic paraplegia (SPG9) that appeared during pregnancy.

Conclusion: In patients with autosomal dominant spastic paraplegia that appeared during pregnancy, amino acid supplementation may be a potential treatment.


Background: The ALDH18A1 gene, encoding delta-1-pyrroline-5-carboxylate synthase (P5CS), is responsible for an autosomal recessive disease with severe developmental delay; more recently, ALDH18A1 was found to be responsible for SPG9, an autosomal dominant (AD) spastic paraplegia.

Methods: We report a three-generation family with AD SPG9, initially suspected because of low citrulline on fasting plasma amino acid chromatography (AAC). Interestingly, in two patients, the spastic paraplegia appeared during pregnancy. One subject presented a severe childhood-onset form while another subject had a mild late-onset disease.

Conclusions: The description of this family is of particular interest: it highlights the possibility of transient or permanent aggravation of spastic paraplegia due to SPG9 during pregnancy, suggesting a direct link between neurological symptoms and amino acid defect in a period of higher requirements and the potential benefit of amino acid supplementation; it underscores the value of plasma citrulline on fasting plasma AAC as a biomarker for this disease; it shows the variable expression of the disease.

Similar Latest Advances